Incyte Corp. Stock
Price
Target price
€102.55
€102.55
-0.300%
-0.3
-0.300%
€109.89
23.07.26 / Tradegate
WKN: 896133 / Symbol: INCY / Name: Incyte / Stock / Biotechnology & Medical Research / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
The full analysis of the stock Incyte Corp. is only available for our menbers.
Not a member yet? Sign up for free!
Not a member yet? Sign up for free!
Financial data and news for Incyte
sharewise wants to provide you with the best news and tools for Incyte, so we directly link to the best financial data sources.
Financials
News
Incyte Sets Mid-Year Phase 3 Trial for CALR Antibody 989 as Pipeline Updates Roll Out
Key Points
- Interested in Incyte Corporation? Here are five stocks we like better.
- Incyte plans to start a Phase 3 trial of mutant CALR antibody 989 in essential thrombocythemia around
Adagene Spotlights ADG126 Strategy as Masked CTLA-4 Trial Advances in Colorectal Cancer
Key Points
- Interested in Adagene Inc. Sponsored ADR? Here are five stocks we like better.
- Adagene’s lead drug ADG126 (muzastotug) is a masked anti-CTLA-4 antibody designed to improve the
Incyte CEO Says Post-Jakafi Growth Path Is Clearer as Pipeline Catalysts Build
Key Points
- Interested in Incyte Corporation? Here are five stocks we like better.
- Incyte’s CEO says the company’s post-Jakafi growth path is becoming clearer as its commercial business
2 Fast-Growing Pharmaceutical Stocks to Buy Now
Incyte (NASDAQ: INCY) and TG Therapeutics (NASDAQ: TGTX) are commercial-stage biotech companies that are using blockbuster drugs to fund the growth of their promising pipelines. Incyte is known for
